Official Title:  Study of Nasal Insulin to Fight Forgetfulness - Device Study
[STUDY_ID_REMOVED]
IRB Approval Date:  12/07/2020
07-December -2020
IND #:  119232
Page 1 of 33 Device Study  for Intranasal Delivery of Insulin  
SNIFF Device  
IND #: [ADDRESS_528676] DIRECTOR  / 
IND SPONSOR  
Suzanne Craft, Ph.D.  
Wake Forest University  
School of Medicine  
Medical Center Boulevard  
Winston -Salem, NC  [ZIP_CODE] -1207  
[EMAIL_7993]  
Tel: 336 -713-8832  
PROTOCOL VERSION  
Final Protocol v 5.0 
07-December -2020
07-December -2020  
IND #:  119232  
Page 2 of 33 TABLE OF CONTENTS  
1.0       INTRODUCTION  ................................ ................................ ................................ ............  8 
1.1 Primary Aim  ................................ ................................ ................................ ................  8 
1.1.1  Secondary Aim 1  ................................ ................................ ................................ .........  8 
1.1.2  Secondary Aim 2  ................................ ................................ ................................ .........  8 
2.0 BACKGROUND AND SIGNIFICANCE ................................ ................................ ..............  8 
2.1 Rationale for Insulin ................................ ................................ ................................ ..... 8 
2.2 Insulin as a Therapeutic Agent  ................................ ................................ ....................  9 
2.2.1  Intranasal Pathways to the CNS  ................................ ................................ ..................  9 
2.2.2  Intranasal Delivery System Devices  ................................ ................................ ..........  10 
3.0 PRELIMINARY STUDIES  ................................ ................................ ................................  10 
3.1 Participants  ................................ ................................ ................................ ...............  11 
3.2 Procedures  ................................ ................................ ................................ ................  12 
3.3 Safety and Compliance  ................................ ................................ .............................  12 
3.4 Statistical Analyses  ................................ ................................ ................................ ... 12 
3.5 Results: Cognitive and Functional Outcome Measures  ................................ .............  13 
3.6 Results: AD Biomarkers  ................................ ................................ ............................  14 
3.7 Results: FDG -PET CMRglc  ................................ ................................ .......................  14 
3.8 Safety and Compliance  ................................ ................................ .............................  15 
3.9 Implications  ................................ ................................ ................................ ...............  15 
4.0 PRELIMINARY STUDY 2  ................................ ................................ ................................  15 
4.1 Rationale for Dosage Selection  ................................ ................................ .................  17 
4.2 Rationale for Primary and Secondary Outcome Measures  ................................ ........  17 
4.3 Rationale for Design of Trial  ................................ ................................ ......................  17 
4.4 Rationale for Biofluids  ................................ ................................ ...............................  17 
5.0 STUDY OVERVIEW  ................................ ................................ ................................ ........  17 
5.1 Study Population  ................................ ................................ ................................ ....... 17 
5.2 Diagnosis Criteria  ................................ ................................ ................................ ...... 18 
5.3  Inclusion Criteria  ................................ ................................ ................................ ....... 18 
5.4 Exclusion Criteria  ................................ ................................ ................................ ...... 18 
5.5 Recruitment and Retention Strategies  ................................ ................................ ....... 19 
6.0 STUDY TIMELINE  ................................ ................................ ................................ ...........  19 
7.0 DESCRIPTION OF STUDY VISITS  ................................ ................................ .................  19 
7.1 Screening (Visit 1)  ................................ ................................ ................................ ..... 19 
7.2 Baseline (Visit 2)  ................................ ................................ ................................ ....... 20 
7.3 Visit 3  ................................ ................................ ................................ ........................  20 
8.0 STUDY -SPECIFIC PROCEDURES  ................................ ................................ .................  20 
8.1 Memory Evaluation Instruments Administered to the Participant  ...............................  20 
8.2 Clinical and Functional Evaluations  ................................ ................................ ...........  20 
8.2.1  Clinical Dementia Rating Scale – Sum of Boxes (CDR -SB) ................................ ....... 20 
9.0 STUDY METHODS  ................................ ................................ ................................ ..........  21 
9.1 Safety Assessments  ................................ ................................ ................................ .. 21 
9.2 Physical and Neurological Examination  ................................ ................................ ..... 21 
9.3 Electrocardiogram (ECG)  ................................ ................................ ..........................  21 
9.4 Clinical Laboratory Evaluations  ................................ ................................ .................  21 
10.0  BIOMARKER STUDIES  ................................ ................................ ................................ .. 21 
10.1  CSF ................................ ................................ ................................ ...........................  21 
10.2  Blood Collection at Lumbar Puncture Visits  ................................ ...............................  22 
07-December -2020  
IND #:  119232  
Page 3 of 33 10.3  Genetic Samples, Storage and Future Use  ................................ ...............................  22 
11.0  STATISTICAL PLAN  ................................ ................................ ................................ ....... 22 
11.1  Power Analyses  ................................ ................................ ................................ ........  22 
12.0  POTENTIAL RISKS  ................................ ................................ ................................ ........  22 
12.1  Safety of Intranasal Insulin  ................................ ................................ ........................  22 
12.2  Risks associated with use of the ViaNase® device  ................................ ....................  23 
12.3  Lumbar Puncture  ................................ ................................ ................................ ....... 23 
12.4  Blood Draw  ................................ ................................ ................................ ...............  23 
13.0  PERSONNEL REQUIREMENTS  ................................ ................................ .....................  23 
14.0  STUDY DRUG  ................................ ................................ ................................ .................  24 
14.1  Humulin® R U-100 Insulin  ................................ ................................ ..........................  24 
14.2  Placebo (Sterile Saline)  ................................ ................................ .............................  24 
14.3  Randomization  ................................ ................................ ................................ ..........  24 
14.4  Blinding  ................................ ................................ ................................ .....................  24 
14.5  Study Drug Dispensing  ................................ ................................ ..............................  24 
14.6  Intranasal Administration  ................................ ................................ ...........................  24 
14.7  Storage  ................................ ................................ ................................ .....................  24 
14.8  Drug Accountability  ................................ ................................ ................................ ... 25 
15.0  ADVERSE EVENTS  ................................ ................................ ................................ ........  25 
15.1  Definition  ................................ ................................ ................................ ...................  25 
15.2  Following Up on AEs  ................................ ................................ ................................ . 25 
16.0  SERIOUS ADVERSE EVENTS (SAE)  ................................ ................................ .............  25 
16.1  Definition  ................................ ................................ ................................ ...................  25 
16.2  Reporting SAEs  ................................ ................................ ................................ .........  25 
17.0  ETHICS & REGULATORY CONSIDERATIONS  ................................ .............................  [ADDRESS_528677] (IRB)  ................................ ................................ ................  26 
17.3  Informed Consent & HIPAA Authorization  ................................ ................................ . 26 
17.4  Participant Confidentiality | HIPAA  ................................ ................................ ............  26 
18.0  GENETIC RESEARCH & STORAGE OF GENETIC MATERIAL  ................................ .... [ADDRESS_528678]  ................................ ..............................  28 
20.0  PUBLICATION POLICY  ................................ ................................ ................................ .. 28 
21.0  SHARING OF FINAL RESEARCH DATA  ................................ ................................ ....... 28 
22.0  TABLE 4: SCHEDULE OF PROCEDURES AND ASSESSMENTS  ................................  29 
23.0  LITERATURE CITED  ................................ ................................ ................................ ...... 30 
  
07-December -2020  
IND #:  119232  
Page 4 of 33 STUDY GLOSSARY  
 
3MSE  MODIFIED MINI -MENTAL STATUS EXAM  
AΒ BETA AMYLOID  
AD ALZHEIMER’S DISEASE  
ADAS -COG  ALZHEIMER’S DISEASE ASSESSMENT SCALE – COGNITIVE 
SUBSCALE  
ADCS  ALZHEIMER’S DISEASE COOPERATIVE STUDY  
ADCS -ADL ALZHEIMER’S DISEASE COOPERATIVE STUDY - ACTIVITIES OF 
DAILY LIVING  
ADEAR  ALZHEIMER’S DISEASE EDUCATION AND REFERRAL CENTER  
ADNI  ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE  
AE ADVERSE EVENT  
AMCI  AMNESTIC MILD COGNITIVE IMPAIRMENT  
ANCOVA  ANALYSIS OF COVARIANCE  
APOE/APOE4  APOLIPOPROTEIN (APOE) EPSILON 4 (APOE4)  
BDNF  BRAIN -DERIVED NEUROTROPHIC FACTOR  
BID | BID  BIS IN DIE (TWICE A DAY)  
BUN  BLOOD UREA NITROGEN  
CDR -SB CLINICAL DEMENTIA RATING – SUM OF BOXES  
CFR CODE OF FEDERAL REGULATIONS  
CMRGLC  CEREBRAL METABOLIC RATE OF GLUCOSE UTILIZATION  
CNS  CENTRAL NERVOUS SYSTEM  
CPD  CONTROLLED PARTICLE DISPERSION  
CPK  CREATINE PHOSPHOKINASE  
CREB  CAMP RESPONSE ELEMENT -BINDING PROTEIN  
CRF/E -CRF CASE REPORT FORM/ELECTRONIC CASE REPORT FORM  
CSF CEREBRAL SPI[INVESTIGATOR_419256] & SAFETY MONITORING BOARD  
DSM -IV DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL 
DISORDERS, FOURTH EDITION  
DSRS  DEMENTIA SEVERITY RATING SCALE  
EAG  ESTIMATED AVERAGE GLUCOSE  
ECG  ELECTROCARDIOGRAM  
EDC  ELECTRONIC DATA CAPTURE  
07-December -2020  
IND #:  [ADDRESS_528679] HEMATOCRIT  
HCY  HOMOCYSTEINE  
HEENT  HEAD | EARS | EYES | NOSE | THROAT  
HGB  HEMOGLOBIN  
HIPAA  HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT  
HOMA -IR HOMEOSTATIS MODEL ASSESSMENT OF INSULIN RESISTANCE  
ICF INFORMED CONSENT FORM  
ICH INTERNATIONAL CONFERENCE ON HARMONISATION  
IDE INSULIN DEGRADING ENZYME  
IGF-[ADDRESS_528680]  
ITT INTENT -TO-TREAT  
LDH LACTATE DEHYDROGENASE  
LP LUMBAR PUNCTURE  
LTP LONG TERM POTENTIATION  
MCV  MEAN CORPUSCULAR VOLUME  
ML MILLILITER  
MMA  METHYLMALONIC ACID  
MMSE  MINI MENTAL STATE EXAMINATION  
MPRAGE  MAGNETIZATION PREPARED RAPID GRADIENT ECHO  
MR/MRI  MAGNETIC RESONANCE / MAGNETIC RESONANCE IMAGING  
NBAC  NATIONAL BIOETHICS ADVISORY COMMISSION  
07-December -2020  
IND #:  119232  
Page 6 of 33 NIA NATIONAL INSTITUTE ON AGING  
NIH NATIONAL INSTITUTES OF HEALTH  
NINCDS/ADRDA  NATIONAL INSTITUTE OF NEUROLOGICAL AND COMMUNICATIVE 
DISEASES AND STROKE / ALZHEIMER'S DISEASE AND RELATED 
DISORDERS ASSOCIATION  
NBDA  N-METHYL – D-ASPARTATE  
NSAID  NON -STEROIDAL ANTI -INFLAMMATORY DRUGS  
OHRP  OFFICE FOR HUMAN RESEARCH PROTECTIONS  
PBMC  PERIPHERAL BLOOD MONONUCLEAR CELL  
PD PROJECT DIRECTOR  
PCP PRIMARY CARE PHYSICIAN  
PET POSITRON EMISSION TOMOGRAPHY  
PHI PROTECTED HEALTH INFORMATION  
PI [INVESTIGATOR_419257]  
T TESLA  
TSH THYROID STIMULATING HORMONE  
U/A URINALYSIS  
WBC  WHITE BLOOD COUNT  
 
  
07-December -2020  
IND #:  [ADDRESS_528681] University Health Sciences  
STUDY PHASE     Phase II  
INDICATION     Preclinical AD, Amnestic mild cognitive impairment (aMCI) or mild 
Alzheimer’s disease (AD)  
AIM OF STUDY  To determine  the ability of an intranasal delivery device (Kurve ViaNase 
device) to increase levels of insulin in cerebrospi[INVESTIGATOR_872] (CSF)  
PRIMARY OBJECTIVE  To test the hypothesis that CSF insulin levels will increase [ADDRESS_528682] (Auditory Verbal Learning Test) will be 
enhanced after insulin administration relative to placebo  
2. To test the hypothesis that the CSF Aβ42/40 and the CSF 
Aβ/tau ratios will increase after insulin administration relative 
to placebo  
PRIMARY OUTCOME MEASURE  CSF insulin  
SECONDARY OUTCOME MEASURES   Memory test, CSF insulin, A 40, A42, total tau, and phospho -tau 181  
STUDY DESIGN   Single -site, double -blind, placebo -controlled study  
SAMPLE SIZE  • n=30 
SUMMARY OF KEY ELIGIBILITY 
CRITERIA   • Cognitively normal or  
•  Diagnosis of aMCI (Petersen criteria)  
• Age: 55 to 85 yrs (inclusive)  
DRUG DOSAGE & FORMULATION  20  International Units  Humulin® R U-100 or matching placebo (saline)  
DURATION OF PARTICIPATION  The approximate timeline for this 21 month study is projected as: 1) 
approximately 1 months for study startup activities including IND 
submission and IRB approval, and training; 2) approximately 18 months 
for data collection ; 3) 2 months for assay and data analysis  
PLACEBO  A matching placebo (sterile saline) will be used  
ROUTE OF ADMINISTRATION   Intranasal  
PROCEDURES   Physical and neurological exam, nasal examination, lumbar puncture, 
Vitals, Clinical Labs, CSF and blood analysis &  banking and 
genotypi[INVESTIGATOR_007].  
 
07-December -2020  
IND #:  [ADDRESS_528683] in 
examin ing a novel therapeutic approach using intranasally administered insulin (INI) that has shown 
promise in short -term clinical trials.  In a recent longer term trial in which INI was delivered with two 
devices  (Kurve ViaNase device and Impel Precision Olfactory Delivery (POD) device , a different pattern 
of results was observed between the two devices, suggesting that differences in delivery systems can 
impact the therapeutic effects of insulin. The proposed proof of concept study will examine whether the 
device t hat was associated with clinical improvement is able to increase CSF insulin levels [ADDRESS_528684] increase in CSF insulin 
in a previous study  (Born et al. Nature Neuroscience,  2002 Jun;5(6):514 -6). If successful, information 
gained from the study will inform the design of future Phase III trials of intranasal insulin.  
 
1.[ADDRESS_528685] (Auditory 
Verbal Learning Test) will be enhanced after insulin administration relative to placebo   
 
 Secondary Aim [ADDRESS_528686] the hypothesis that the CSF Aβ 42/40  and the CSF Aβ 42/tau ratio s will increase after 
insulin administration relative to placebo  
 
2.0 BACKGROUND AND SIGNIFICANCE  
 
2.1 Rationale for Insulin  
The rationale for the study is derived from growing evidence that insulin carries out multiple functions 
in the  brain, and that insulin d ysregulation may contribute to AD pathogenesis  (Craft and Watson 2004 ). 
Insulin receptors are densely  localized in the hippocampus and in entorhinal, frontal, and other cortical 
areas; they are found primarily in  synapses, where insulin signaling modulates  synaptogenesis and 
synaptic remodeling  (Chiu, Chen et al. 2008 , Zhao and Townsend 2009 ). Insulin facilitates memory at 
optimal levels, possibly  through synaptic effects and enhanced hippocampal glucose utilization  (Grillo, 
Pi[INVESTIGATOR_360900]. 2009 ).  
 
The importance of insulin in normal brain function is  underscored by [CONTACT_419269], a disorder  characterized in its earliest stages by [CONTACT_419270]. Hoyer and colleagues first  identified a reduction in insulin receptors and 
signaling markers in the AD brain  (Frolich, Blum -Degen et al. 1998 ). This initial finding has been  
confirmed and extended by [CONTACT_127761], who have demonstrated reduced CSF insulin in patients 
with AD and MCI  (Craft, Peskind et al. 1998 , Gil-Bea, Solas et al. 2010 ), and reduced insulin and IGF -
I messaging with increasing AD pathology and cholinergic  deficit  (Rivera, Goldin et al. 2005 ). Insulin 
has a close relationship with β -amyloid, the toxic peptide produced by [CONTACT_419271]  (Zhao and Townsend 2009 ). In AD, insoluble Aβ peptides deposit in brain parenchyma and 
vasculature. Soluble Aβ  species, particularly oligomers of the 42 amino acid specie (Aβ42), have 
synaptotoxic effects, possibly  resulting in synapse loss, which is the earliest structural defect observed 
in AD  (Selkoe 2008 ). Insulin reduces oligomer  formation and protects against Aβ -induced 
07-December -2020  
IND #:  119232  
Page 9 of 33 synaptotoxicty  and LTP disruption  (Gasparini, Gouras et al. 2001 , De Felice, Vieira et al. 2009 , Lee, 
Kuo et al. 2009 ). Interestingly, Aβ also  regulates brain insulin signaling. Soluble Aβ binds to the insulin 
receptor and disrupts insulin signaling and LTP  induction in mouse hippocampal slice preparations  
(Townsend, Mehta et al. 2007 ). These effects could be prevented by [CONTACT_419272] 
Aβ exposure. Insulin pre -treatment also prevented synthetic soluble Aβ oligomers from  downregulating 
plasma membrane insulin receptors and reducing dendritic spi[INVESTIGATOR_360901]  (De 
Felice, Vieira et al. 2009 ). Insulin may also modulate Aβ degradation by [CONTACT_419273]  (IDE), a metalloprotease that catabolizes insulin  (Zhao, Teter et al. 2004 ). 
Collectively, these findings suggest that soluble Aβ  may induce central nervous system ( CNS ) insulin 
resistance and synapse loss, and that treatment with insulin may prevent  these pathological processes . 
 
A role for insulin has also been suggested for other AD -related mechanisms. Insulin inhibits  
phosphorylation of tau, through its regulation of glycogen synthase kinase 3β, a downstream target in 
the insulin  signaling pathway  (Hong and Lee 1997 ). Insulin dysregulation is also associated with 
oxidative stress, inflammation, and  impaired neurogenesis  (Craft and Watson 2004 ). Thus, insulin has 
been implicated in numerous processes related to AD  pathophysiology, suggesting that correction of 
insulin dysregulation may be a therapeutic strategy  with considerable clinical and scientific significance.  
 
2.[ADDRESS_528687] to the majority of therapeutic approaches that focus on  narrowly defined 
mechanisms such as acetylcholine modulation or amyloid accumulation. Restoring normal  brain insulin 
levels in persons with AD ma y improve cognition and AD pathologic processes. Such an approach  is 
possible with an intranasal administration technique.  
 
 Intranasal Pathways to the CNS   
Olfactory sensory neurons are directly exposed to the external  environment in the upper nasal cavity 
while their axons extend through the cribriform plate to the olfactory bulb.  Following intranasal 
administration, drugs can be directly transp orted to the CNS, by[CONTACT_419274].  Several 
extraneuronal and intraneuronal pathways from the nasal cavity to the CNS are possible. The  
extraneuronal pathways appear to rely on bulk flow transport through perineural channels to the brain 
or CSF.  In recent studie s, labeled INI or a closely related peptide, insulin -like growth factor -I (IGF -I), 
were administered  to rodents  (Thorne, Pronk et al. 2004 , Francis, Martinez et al. 2008 ). Within [ADDRESS_528688] was identified  with quick 
access to the CSF after absorption into the submucosa along the olfactory nerve and cribriform  plate  
(Born, Lange et al. 2002 , Frey 2002 , Thorne, Pronk et al. 2004 ). These extracellular pathways provide 
direct access to the CNS within minutes of intranasal  administration. Additionally, an intraneuronal 
pathway delivers drugs to the CNS hours or days later (Broadwell and Balin 1985 , Shipley 1985 , Baker 
and Spencer 1986 , Balin, Broadwell et al. 1986 ). Viruses and microorganisms  (Fairbrother and Hurst 
1930 , Faber 1938 , Bodian and Howe 1941 ), amino acids  (Weiss and Holland 1967 ), and proteins  
(Kristensson and Olsson 1971 , Shipley 1985 , Thorne, Emory et al. 1995 ) can also enter the CNS via 
nasal routes. In particular, substances with lower molecular weights are more likely to be transported 
to the CNS along intranasal pathways  (Sakane, Akizuki et al. 1995 ). Insulin’s molecular weight of about 
5800 g/mol makes it a good candidate for intranasal delivery.  Animal studies show labeled uptake to 
hippocampus and rostral and caudal cortex following INI  administration  (Francis, Martinez et al. 2008 ). 
In a murine diabetes model, INI reduced brain atrophy, while increasing synaptic markers and activation 
of Akt, CREB , and [COMPANY_004]3β. Memory enhancement was also observed on Water Maze and radial arm  
tasks  (Francis, Martinez et al. 2008 ). Human functional and cognitive studies of INI also support insulin’s 
transport to the CNS. INI treatment  increases CSF insulin levels and induces changes in auditory -
evoked brain potentials compared to placebo  (Kern, Born et al. 1999 ). INI improves verbal memory 
07-December -2020  
IND #:  119232  
Page 10 of 33 acutely in persons with AD  and aMCI without affecting  plasma insulin or glucose levels at the dose 
included in the study  (Reger, Watson et al. 2006 ). Regarding chronic effects,  several studies reported 
that 2 months of daily insulin administration (160 International Units /day) significantly improves verbal  
memory in young healthy adults  (Benedict, Hallschmid et al. [ADDRESS_528689], de Fries et al. Submitted for 
publication ). Finally, Section 3.[ADDRESS_528690]:  
 
1) An investigational device  (ViaNaseTM) developed  by [CONTACT_419275] (Bothell, WA)  will be 
used in this study;  the current device is identical  to the model used two studies approved by [CONTACT_419276] , SNIFF Long , IRB number [ADDRESS_528691]. Carol Bushnell’s study of 
Intranasal Insulin and Post Stroke Cognition, IRB00029022 .Typi[INVESTIGATOR_419258] 20% of the lower nasal cavity, and 
due to gravity and insufficient  airflow, ~90% of the droplets wind up in the stomach. Th e 
ViaNaseTM device delivers a substance throughout the nasal cavity  (to the olfactory region and 
paranasal sinuses ), thereby [CONTACT_419277] -to-brain channels. This controlled 
particle dispers ion (CPD)  occurs  because droplet size is adjusted according to the weight of the  
substance through an individually optimized droplet generator  resulting in maximal v ertical 
distribution . 
 
3.[ADDRESS_528692] of 4-month INI administration using the ViaNase  device (10 
or 20 International Units  bid vs. placebo) on the primary outcome measure s of delayed story recall and 
the Dementia Severity Rating Scale (DSRS) as well as on measures of global cognition and function 
used in traditional AD clinical  trials. In a subset of participants, effects on CSF AD biomarkers (Aβ42 
and tau/Aβ42 ratio),  and on cerebral metabolic rate of glucose utilization (CMRglc) assessed by 
F18FDG PET  were also examined (Craft, Baker et al. 2012 ). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-December -2020  
IND #:  119232  
Page 11 of 33  
3.1 Participants  
A total o f 111 older adults were 
randomized in the study (Fig. 1). Data 
from 104 participants were analyzed.  
 
Sample composition (aMCI, n=64; AD  
with MMSE  >15, n=40), size, and 
diagnostic criteria were  based on a 
previous study  (Reger, Watson et al. 
2008 ). Forty  participants (15 placebo, 13 
low dose insulin and 12 high dose 
insulin) comp leted the PET sub -study, 
and 23 participants (n=8 placebo and 15 
insulin) completed the LP sub -study. 
Diagnoses were determined by [CONTACT_360937]. Participants, caregivers, and 
all personnel involved in data  collection 
were blinded to treatment assignment. 
Groups did not differ in education, body mass index, MMSE,  gender, diagnosis, cholinesterase 
inhibitor  treatment, or apolipoprotein E (APOE) ε4 allele  carriage (Table 1).  
 
Table 1 | Participant  Characteristics  
 
 
Participants in the high dose  insulin group were younger than placebo -assigned  participants (p=0.02), 
whereas no differences were  observed between placebo and low dose insulin  groups. Age was included 
as a covariate in all  analyses.  
Figure 1 | Trial Enrollment Flow  
07-December -2020  
IND #:  119232  
Page 12 of 33 3.2 Procedures  
Participants were  randomized to receive 10 International Units  INI bid for a total daily  dose of 20 
International Units  INI (n=36), 20 International Units  INI bid for a total dose  of 40 International Units  
(n=38) or placebo (saline bid, n=30) for 4  months. Participants were stratified by [CONTACT_291292] -ε4 carriage. 
Saline or insulin (Novolin R, Novo) was  administered after breakfast and dinner with ViaNase ™, an 
intranasal delivery system  (Craft, Baker et al. 2012 ). Parallel versions  of the cognitive protocol were 
administered at  baseline, and months 2 and 4 of treatment. Co -primary outcome measures were  
delayed story recall and the DSRS  which had previously demonstrated  beneficial effects of insulin  
(Reger, Watson et al. 2008 ). Secondary measures included the AD  Assessment Scale for Cognition 
(ADAS -Cog) (Reger, Watson et al. 2008 ), a test comprised of  measures of memory, orientation, and  
language, with higher scores reflecting  impairment ranging from 0 (best) to 70  (worst), and the ADCS -
Activities of Daily Living scale (ADCS -ADL)  (Galasko, Bennett et al. 1997 ). Baseline and post-treatment 
fasting CSF was analyzed for Aβ42 and tau with multi -parameter bead -based  immunoassay INNO -BIA 
AlzBio3 (Innogenetics NV). Resting PET images w ere obtained using a GE Advance PET scanner (GE 
Medical Systems, Milwaukee, WI) using a previously described protocol  (Baker, Cross et al. 2011 ). 
 
3.3 Safety and Compliance  
Support persons supervised participants’ intranasal administration. Blood  glucose was measured daily 
for the first week and then weekly; no group changes were observed over the  course of the s tudy (Craft, 
Baker et al. 2012 ). Compliance was monitored by [CONTACT_419278]. Safety d ata were reviewed 
semi -annually by a Data and Safety Monitoring Board. Adverse event reporting followed standard 
guidelines.  
 
3.4 Statistical Analyses  
For the intent -to-treat (ITT) sample, co -primary (delayed story recall  and DSRS)  and secondary (ADAS -
Cog and ADAS -ADL) scores were log transformed. Scores were first subjected to  mixed model repeated 
ANCOVA including all treatment groups (placebo, low dos e insulin or high dose insulin) as the between 
subjects factor, and time (baseline, month 2, month 4) as the repeated factor using the SAS  v9.2 
General Linear Models procedure. After a significant (p<0.05) time by [CONTACT_419279] a di fferent pattern of change, each of the two insulin groups was compared separately with 
the placebo group using repeated measures ANCOVAs. Effect sizes (Cohen’s f 2) were calculated for 
all significant  effects. Age was included as a covariate in all analyses. Diagnosis (aMCI or AD), gender, 
APOE -ε4 carriage  status (yes or no), baseline 3MSE score,  and years of education we re also included 
as covariates. Non-significant  covariates were dropped from the model. Significant relationships with 
covariates were explored  with Pearson correlation (continuous variables) or follow -up ANOVAs (class 
variables). Missing values were  treated with multiple imputation  (Rubin 1987 ). For exploratory CSF 
biomarker analyses, because only a subset of  participants elected to undergo LP and no differences 
were observed between the two insulin dose arms,  the groups were combined into a single insulin -
treated group to maximize power. Biomarkers were analyzed with  the repeated ANCOVA strategy 
described above and , due to the small sa mple size, exploratory Spearman correlations were conducted 
to examine relationships among changes in biomarkers and outcome measures.  Only study completers 
underwent post -treatment FDG -PET. Pre  and post treatment scans were co -registered  within subject 
and anatomically standardized to Talairach and Tournoux stereotactic coordinates  (Talairach and 
Tournoux 1988 , Minoshima, Koeppe et al. 1994 ). Pi[INVESTIGATOR_360903]  
(Minoshima, Frey et al. 1995 ). Interval regional CMRglc changes within groups were assessed  using 
voxel -wise one -sample t statistics (pre -/post -treatment pair) and probability integral conversion to z  
scores  (Worsley, Evans et al. 1992 ). Interval changes in regional CMRglc were then compared between 
1) low insulin vs. placebo groups,  and 2) high insulin vs. placebo groups. Based on the number of voxels 
and smo othness of the statistical map, a Type I error rate was controlled at 0.05 to account for multiple 
comparisons  (Worsley, Evans et al. 1992 ). The resulting statistical maps  were visualized in three -
dimensional stereotactic surface projections.  
 
07-December -2020  
IND #:  119232  
Page 13 of 33 3.5 Results: Cognitive and Functional Outcome Measures  
The three groups di d not differ at baseline on any outcome measure; change from baseline is 
represented in figures for ease of interpretation. A significant  overall treatment group by [CONTACT_419280] (p=0.005).  Compared to placebo, the low dose 
group had improved delayed recall (Fig. 2A; treatment by [CONTACT_5586] p=0.02,  
Cohen’s f 2=0.36), whereas no effect was observed for the high dose group . Exploratory post -hoc 
analyses were then conducted to more closely examine the relationship of insulin dose to story recall, 
as this was a  primary goal of this pi[INVESTIGATOR_29833]. Given findings that delayed recall may not be a 
sensitive measure for AD  subjects due to increased variability and floor effects  (Sano, Raman et al. 
2011 ) we constructed a total story recall score (immediate and delayed), which showed improvement 
for the high -dose group (time by [CONTACT_9866] p<0.05, mean log total story recall change score 
with SEM = -.15(.1) for placebo vs.12 (.09) for the high dos e group). A significant overall treatment by 
[CONTACT_360941], the DSRS (p=0.008). Compared 
with placebo, DSRS scores were preserved for both low and high dose groups ( Fig.2B; trea tment by 
[CONTACT_360942]=0.01 an d 0.01, Cohen’s f 2=0.38 and 0.41). For  secondary measures, significant effects  were 
observed for the ADAS -Cog (overall treatment by [CONTACT_6491]  p=0.004). Both low and high insulin 
groups had less decline in cognition compared with placebo ( Fig. 2C; treatment by [CONTACT_360942]=0.04 and 
p=0.002,  Cohen’s f2=0.27 and .40). Treatment  effects on the  ADAS -Cog interacted with age; for the 
high dose insulin group,  greater improvement (lowered score) tended to be associated with younger  
age (r=.31, p=0.06). For the ADCS -ADL, no overall effects of treatment on daily function were observed.  
However, a significant interaction with diagnosis was observed for this measure (overall treatment by 
[CONTACT_360943] p=0.02). Participants with AD receiving either dose of insulin had 
preserved function compared with placebo -assigned participants with AD who showe d slight decline, 
whereas participants with aMCI showed no change regardless of treatment assignment (interactions 
for the participants with AD in low and high dose groups compared with placebo, ps=0.01 and 0.02, 
Cohen’s f=0.45 and 0.43; Fig. 2D). Adjustme nt for APOE -ε4 status, baseline MMSE score, 
cholinesterase inhibitor treatment,  gender, and  education did not affect the pattern of any result.  
Figure 2 | Change (Month 4 -baseline) in log scores for (A) delayed story recall, (B) DSRS, (C) ADAS -Cog 
and (D) ADCS -ADL.  
 
 
 
 
 
 

07-December -2020  
IND #:  119232  
Page 14 of 33 3.6 Results: AD Biomarkers   
CSF Aβ42, Aβ40 and tau did not change for the placebo or insulin -treated groups as a whole. In 
exploratory analyses, however, for insulin -treated participants , increased CSF Aβ42  concentrations 
were associated with improved delayed story recall and ADCS -ADL score s, whereas decreased  Aβ42 
was associated with worse performance (Spearman rhos=.59, p=0.02 and .60, p=0.02). Similarly,  
decreased tau/Aβ42 ratios over the 4 -month study period correlated with improved delayed story recall 
and better daily function on both ADAS -ADL and DSRS for insulin -treated participants (Spearman 
rhos= -.52, p=0.05, -.50, p=0.07, and .53, p=0.05). No significant correlations were observe d for the 
placebo group.  
 
3.7 Results: FDG -PET CMRglc  
Compared with placebo -assigned participants, the lower dose insulin group  showed reduced 
progression of hypometabolism in bilateral frontal, right temporal, bilateral occipi[INVESTIGATOR_307], and right  precuneus  
and cuneus regions over the 4 -month treatment  period (Fig. 3 and Table 2). The higher  dose insulin 
group showed even greater  treatment effects  (higher Z scores)  indicating less  hypometabolism  
progression in most  regions and in left  parietal cortex.  
 
Figure 3 | Areas of hypometabolism at baseline (scan 1) and month 4 (scan 2), along with changes in 
hypometabolism (time 2 -time 1) within each group and differences in change between placebo and low or 
high insulin groups (nasal insulin -placebo).  Hotter floors in dicate areas of greater hypometabolism from 
time 1 to time 2, and from placebo to insulin groups.  
 
 
Table 2 | Z scores and stereotactic coordinates for areas of reduced progression for low and high does 
insulin groups compared to placebo  
 
 

07-December -2020  
IND #:  119232  
Page 15 of 33 3.8 Safety and Compliance  
No treatment -related serious adverse events ( SAEs ) occurred during the study; most adverse events 
(AEs) were  minor, such as mild rhinitis. AEs with an occurrence of >5% in any group are listed in Table 
3. The total AE  mean was higher for the low dose group compared with placeb o (low dose mean total 
AEs with standard  error=1.44 ±0.20, placebo =0.80 ±.22, p=0.04), with a similar trend for the high dose 
and placebo group  comparison (high dose mean total AEs =1.21 ±0.16, placebo =0.80 ±.22, p=0.10). 
Mean compliance (number of completed doses) ranged from 95 -97% and did not  differ across groups.  
Table 3 | Total number of adverse events and per cent of sample for all events occurring for at least 5% of 
the participants in any treatment group.  
 
 
3.[ADDRESS_528693] that adults with aMCI or AD may benefit  from INI treatment . Compared with 
placebo,  the lower dose of insul in improved delayed memory, and both insulin doses preserved 
caregiver -rated ability to  carry out daily functions. General cognition as assessed  with the ADAS -Cog, 
the primary outcome measure for the  current  trial, was also preserved by [CONTACT_419281]. In  
exploratory analyses, changes in CSF Aβ42 and tau/Aβ42  ratios were  associated with cognitive and 
functional  changes for insulin -treated participants. Placebo -assigned  participants showed  decreased 
CMRglc values in frontal, temporal, and parietal cortices as well as  precuneus  and cuneus over th e 4-
month period, whereas insulin -treated participants showed no decline. The  longstandi ng FDG PET 
finding of posterior cingulate , precuneus  and cuneus hypometabolism in AD has been  hypothesized to 
be due to functional disconnection of the hippocampal formation, so enhanced metabolism  and memory 
with INI may reflect enhanced hippocampal input to this region. Similarly there are strong  connections 
betw een the posterior cingulate, precuneus , cuneus and prefrontal and superior temporal cortex  
(Cavanna and Trimble 2006 ), which may also be affected by [CONTACT_360945]. Finally, no treatment -related SAEs 
occurred. These promising results  provide a strong rationale for the longer, larger, multi -site trial 
proposed in this application . 
 
4.[ADDRESS_528694] been analyzed . 
 
Objectives:  This study tested  the effects of 40 International Units  of intranasal insulin administered 
daily for 12 months , compared with placebo, on cognition , daily function and safety in adults with MCI 
or mild AD. Longer -term effects were examined in a six -month open -label extension offered to all 
participants. Safety and feasibility issues relating to the use of intranasal delivery devices were also 
evaluated. The trial is nearing completion;  all participants h ave concluded the blinded phase.  
 
Methods:  Twenty -six sites enrolled 2 89 participants with MCI or mild AD in this randomized, double -
blind , Phase II/III trial ( [STUDY_ID_REMOVED] ). Adults 55 to 85 years of age  with diagnoses of amnestic MCI 
or AD (National Institute on Aging -Alzheimer’s Association criteria) with Mini -Mental State Exam 
(MMSE) scores >19, Clinical Dementia Ratings (CDR) of 0.5 or 1, and delayed Logical Memory 
scores within a specified education -adjusted range were eligible. Participants with diabetes requiring 
medication were excluded, as were participants who had used insulin within one year of the screening 

07-December -2020  
IND #:  119232  
Page 16 of 33 visit. Participants were randomized on a 1:1 basis using a  covariate -adaptive  algorithm that weighted 
MMSE , apolipoprotein E -4 (APOE -4) allele carriage, study site, sex, and age based on previous 
work indicating these factors may impact treatment response. Participants received  40 International 
Units  of insulin or insulin diluent placebo (Humulin R U -100 or insulin diluent , Eli Lilly, Indianapolis, 
[LOCATION_003]) daily for 12 months. At the end of the 12 -month blinded phase, all participants were  offered 
open -label  insulin treatment for 6 months.  The primary outcome (Alzheimer’s Disease Assessment 
Scale for Cognition -12/ADAS -Cog12)  was administered at baseline and then at 3 month intervals. 
Secondary functional outcome s (Alzheimer’s Disease Cooperative Study -Activities of Daily Living 
Scale for MCI; CDR Sum of Boxes) were assessed at 6 month intervals, as was a memory composite 
(Free and Cued  Selective Reminding Test and Story Recall) . Cerebrospi[INVESTIGATOR_417733] (A 42 
and A42/tau ratio) and magnetic resonance i maging hippocampal and entorhinal cortex volumes 
were measured at baseline and after [ADDRESS_528695] 
49 participants, the delivery device had frequent malfunctions (i.e. failure to turn on) that impacted 
dosing reliability. At that time, a newly availabl e device was introduced ( Precision Olfactory 
Device /POD, Impel NeuroP harma, Seattle, [LOCATION_003] ) which was used by [CONTACT_41757] 240 participants 
with good reliability.  
 
Results:  Demographic characteristics of enrolled participants are 
presented in Table 1. Retention was excellent, with  only [ADDRESS_528696]  any safety issues and 
approved unmodified continuation of the trial.  
 
Data from the subgroup of participants who used the POD were 
analyzed separately from the ViaNase group. The primary 
analysis of the POD group showed was negative; no difference in ADAS -Cog12 scores were 
observed after 12 months of INI treatment compared with placebo (Fig.1). In contrast, analysis of the 
ViaNase group showed beneficial effects of insulin compared with placebo; the effect was significant 
at 6 months (p<0.01), and persisted at 12 months (p=0. 09; Fig. 2).  
  
 
 
Implication : These results suggest that the two delivery devices may be providing different doses of 
insulin to the CNS. The ViaNase device results are consistent with multiple previous studies. The 
POD had not been used previously in clinical trials with insulin, and th us was relatively untested in 
terms of delivery efficacy, although modeling in organoid nasal cavities was conducted to verify that 
the target amount of insulin was dispersed to the target location in  the nasal cavity. These divergent 
results can potential ly be clarified by [CONTACT_14664] a proof of concept study, in which insulin or placebo 
will be administered and then insulin in CSF will be measured 30 minutes after administration. Results 
Table 1. Baseline Participant 
Characteristics  
N (F/M)  289 (134  / 155) 
Age (years)  70.95  7.1 
Diagnosis (MCI/AD)     105 / 184  
MMSE    24.8  2.7 
Logical Memory      2.1  2.7 
APOE (4+/4-)     193 / 96  
p=0.01p=0.12p=0.09ADAS12	 Mean	 Change	 from	 BL	 for	 ViaNase
§Insulin§Placebo
Fig. 1  Fig. 2  
07-December -2020  
IND #:  119232  
Page 17 of 33 of this proof of concept study will help confirm the delivery capabilities of the V iaNase device, 
information that is essential to the design of a future Phase II I trial.  
 
4.1 Rationale for  Dosage Selection  
The dosage selected (20 International Units  INI) has been used in two prior studies  with positive results 
as described above . 
 
4.[ADDRESS_528697] increases observed 30 minutes after 
administration (Born et al. Nature Neuroscience,  2002 Jun;5(6):514 -6). The observation that CSF levels 
are increased following insulin administration with the ViaNase device will validate that insulin was 
delivered to the CNS and thus that the positive results for the ADAS -Cog12 for the POD cohort in the  
recent study are possibly due to its ability to successfully deliver insulin to the CNS . 
 
Regarding secondary measures, in previous stud ies intranasal insulin acutely improved memory 
performance and affected CSF levels of AD biomarkers  (Reger et al.  2008; Craft et al. 2012).  Thus 
examining effects on these measures will provide supportive information about access to and efficacy 
in the CNS.  
 
4.[ADDRESS_528698] cognitive benefit was observed for adults  with AD who  were not ε4 carriers  (Reger, Watson 
et al. 2008 ). The current  study will examine ε4 carriage as a treatment response predictor.   
 
5.[ADDRESS_528699] of a single site, randomized , double -blind trial comparing the acute effects of INI 
(20 International Units ) or placebo delivered with the ViaNase device on CSF insulin levels, AD 
biomarkers and memory . At study entry, participants will be randomized to receive either an acute dose 
of insulin or of placebo  first, and the other substance on a second visit . Participants who are cognitively 
normal or who have aMCI (n= 30) will be enrolled. The primary outcome measure will consist of CSF 
insulin levels. Secondary measures will include a me mory test and CSF biomarker levels.  
 
5.[ADDRESS_528700] to enroll approximately 50% of participants from each group. To determine eligibility , all 
participants will undergo cognitive assessment, physical and neurological examination, ECG, 
clinical/safety laboratory assessment , and interview s of the participant and study partner  conducted by 
[CONTACT_419282]’s Disease Research Center 
(ADRC).  
 
 
 
07-December -2020  
IND #:  [ADDRESS_528701] 
ADRC  using criteria specified by  [CONTACT_419283]’s Association MCI workgroup  (Petersen, Doody 
et al. 2001 , Albert, Dekosky et al. 2011 ). 
 
Criteria for cognitively normal adults:  
a) No evidence of significant cognitive impairment on objective testing  
b) Clinical Dementia Rating Scores of 0  
 
Diagnosis of aMCI requires:  
a) Evidence of a decline in epi[INVESTIGATOR_10682] (memory scores below age and education -based 
norms)  
b) General preservation of independence in functional abilities  
c) Absence of dementia   
 
5.3  Inclusion Criteria  
The following inclusion criteria * will be used:  
1. Age 55 to 85 ( inclusive)   
2. Fluent in English  
3. Cognitively normal or d iagnosis of aMCI by [CONTACT_419284]  
4. MMSE ≥ [ADDRESS_528702] 0-0.5 (inclusive)  at screening  
6. Stable medical condition for [ADDRESS_528703] be judged to be 
clinically insignificant by [CONTACT_5989]   
*Exceptions to these criteria may be considered on a case -by-case basis at the discretion of the Project 
Director  and study physician , and must be approved in advance by [CONTACT_1201] . 
 
5.4 Exclusion Criteria  
The following exclusion criteria * will be used:  
1. A diagnosis of dementia  
2. History of a clinically significant stroke  
3. Current evidence or history in past two years of epi[INVESTIGATOR_002], focal brain lesion, head injury with 
loss of consciousness or DSM IV criteria for any major psychiatric disorder including psychosis, 
major depression, bipolar disorder, alcohol or substance abuse  
4. Sensory impairment that would preclude the participant  from participating in or cooperating with 
the protocol  
5. Diabetes (type I or type II)  requiring pharmacologic treatment (including both insulin dependent 
and non -insulin dependent diabetes mellitus)  
6. Current or past use of insulin or any other anti-diabetic medication  within  5 years  of Screening 
visit.  
7. Evidence of any significant clinical disorder or laboratory finding including clinically significant 
or unstable hematologic, hepatic, cardiovascular, pulmonary, gastrointestinal, endocrine, 
07-December -2020  
IND #:  119232  
Page 19 of 33 metabolic, renal or other systemic disease or laboratory abnormality  
8. Active neoplastic disease, history of cancer five years prior to screening (history of skin 
melanoma or stable prost ate cancer are not exclusionary ) 
9. History of seizure within past five years  
10. Pregnancy or possible pregnancy . Participant is not pregnant, lactating, or of childbearing 
potential (i.e. women must be two years post -menopausal or surgically sterile)  
11. Contraindications to LP : prior lumbosacral spi[INVESTIGATOR_79477], severe degenerative joint disease or 
deformity of  the spi[INVESTIGATOR_050], platelets <100,000 or history of a bleeding disorder  
12. Use of anticoagulants  warfarin (Coumadin) and dabigatran (Pradaxa) (due to  LP requirement)  
13. Residence in a skilled nursing facility at screening  
14. Use of an investigational agent within two months of screening visit  
15. Regular use of narcotics, anticonvulsants, medications with significant anticholinergic activity, 
antiparkinsonian medications , or any other exclusionary medications  
*Exceptions to these criteria may be considered on a case -by-case basis at the discretion of the Project 
Director  and Study Physician , and must be approved in advance by [CONTACT_1201] . 
 
5.[ADDRESS_528704] ADRC. Some participants 
may also be identified from community recruitment efforts.  
 
6.0 STUDY TIMELINE   
The approximate timeline for this twenty -one-month  study  is projected as follows:  1) approximately one 
months for s tudy startup activities ; 2) study visits and data collection will occur over a n eighteen -month 
period; 3)  CSF and blood analyses , data analyses and study dissemination will occur over the final 2 
months.  
 
7.0 DESCRIPTION OF STUDY VISITS  
The “ Schedule of Study Procedures and Assessments ” in Table [ADDRESS_528705] not previously received APOE 
genotypes through the ADRC .  
 
7.1 Screening (Visit 1)  
The purpose of this visit is to determine study eligibility.  Potential participants must sign an informed 
consent form  and HIPAA Authorization  prior to administration of any study -related procedures. After 
consent is obtained, participant s will be given the MMSE , the CDR  and Story Recall to determine study 
eligibility.  Screening may be waived for participants who have received evaluations  from the ADRC 
within the past 12  months.  
 
In addition,  information regarding demographics, concurrent medications, medical history and adverse 
events will be gathered from the participant. Vital signs , height and weight  will be measured.  A brief 
physical and neurological examination  (which include a nasal examination)  and a standard [ADDRESS_528706] 12-months . 
 
 
07-December -2020  
IND #:  119232  
Page 20 of 33 Blood will be drawn for routine clinical laboratory evaluations.  If value s are  outside of  the laboratory’s 
normal range and de termined  clinically significant  by [CONTACT_093] , lab tests may need to be repeated  
and may be considered exclusionary for participation in the study . Blood samples will also be collected 
for ApoE ge notypi[INVESTIGATOR_419259].   
 
7.2 Baseline (Visit 2)  
Results from all screening procedures must be reviewed and all inclusion/exclusion criteria must be met 
prior to  proceeding to baseline . For participants whose screening visit was waived because they had 
received ADRC evaluations within  the past [ADDRESS_528707]. CSF 
samples will be used to measure levels of insulin, A42, A40, total tau, and phospho -tau181 . 
Additionally, CSF sample will be banked for future exploratory analysis.  CSF will be collected and 
immediately frozen upright on dry ice . Site staff will call the participant within 24 hours from the lumbar 
puncture procedure to inqui re about the participant’s well -being and  possible adverse events . Following 
the lumbar puncture, the delayed recall section of the AVLT will be administered. Participants will then 
receive a snack and instructions about post -lumbar puncture care.  
 
7.3 Visit 3 
Visit 3  will be scheduled within 2 to 6 weeks following Visit 1. V ital signs  and weight will be obtained , a 
nasal  examination will be conducted , adverse events and concurrent medications wi ll be recorded . 
Procedures will follow the schedule outlined for Visit 1, except that the alternate compound (either saline 
or 20 International Units  insulin) will be administered.  
 
8.[ADDRESS_528708].  
 
8.2 Clinical and Functional Evaluations  
 
 Clinic al Dementia Rating Scale – Sum of Boxes (CDR -SB) 
The CDR (Hughes, Berg et al. 1982 , Morris 1993 ) is a clinical scale that rates the severity of dementia 
as absent, questionable, mild, moderate, or severe (CDR score of 0, 0.5, 1, 2, or 3, respectively). The 
score is based on interviews with the participant and study partner, using a structured intervi ew that 
assesses six domains: memory, orientation, judgment and problem solving, community affairs, home 
and hobbies, and personal care.  
 
At Screening the CDR global score will be used  for eligibility purposes . For all other administrations, 
the 6 domain scores will be summed to get the S um of Boxes  (SB) score. Training on the use of the 
CDR will be conducted to standardize its administration across sites. The CDR online training tool 
resides on the Washington University, St. Louis website, with oversight provided by [INVESTIGATOR_124]. J ohn C . Morris  
(Morris, Ernesto et al. 1997 ). 
 
 
 
07-December -2020  
IND #:  119232  
Page 21 of 33 9.0 STUDY  METHODS  
 
9.1 Safety Assessments  
At each study visit, all participants will undergo a nasal  examination and any occurrence of adverse 
events will be reviewed and documented ; concomitant medications will be recorded  as well. In addition, 
24 hours after the Lumbar Puncture , each study participant, or a pers on designated to speak for them  
will be contact[CONTACT_419285]’s  well being and quer ied about any new adverse 
events.  All adverse events will be reported to the Wake Forest  DSMB . Safety  reports will be prepared 
by [CONTACT_419286].  
 
9.2 Physical and Neurological Examination  
A brief physical examination will be performed by a medically qualified professional at the screening 
visit. A review of the major body systems will be performed for example: skin, 
head/ears/eyes/nose/throat (HEENT), cardiovascular, pulmonary, abdomen, musculoskeletal, 
neurological, and gastrointestinal. Assessments of height (Screening visit only), weight, and vital signs 
(systolic and diastolic blood pressure, pulse, temperature, and respi[INVESTIGATOR_1516]) are included.  Neurological 
examination will include an assessment of cranial nerves, strength, coordination, reflexes, sensation, 
tremor and gait at every study visit . A nasal examination will also be performed. The examination will 
assess irritation or other abnormalities of the nares.  
 
9.3 Electrocardiogram (ECG)  
A standard 12 -lead resting ECG will be performed at Screening visit.  The ECG report will be reviewed, 
signed, and dated by [CONTACT_093].  Those with clinically significant ECG findings will be referred for 
follow -up as deemed appropriate by [CONTACT_360955] . 
  
9.4 Clinical Laboratory Evaluations  
All routine laboratory samples will be analyzed by a central laboratory, which will provide a procedures 
manual and supplies. Lab reports will be reviewed, signed and dated by [CONTACT_38234] .  If a value 
is outside of the laboratory’s normal range, the clinician  will indicate if it is clinically significant or not. If 
clinically significant, lab tests may need to be repeated  and follow up with the participant’s PCP  should 
occur .    
 
10.[ADDRESS_528709].  
Participants who are taking anticoagulants, warfarin (Coumadin) and dabigatran (Pradaxa) should not 
be screened for this trial , as these are prohibited medications. Based on clinician judgment and 
depending on the clinical indication, it may be suitable to discontinue participants from their anti -platelet 
agent (e.g., aspi[INVESTIGATOR_248], Plavix, NSAIDs) for [ADDRESS_528710] 24 hours 
after lumbar puncture.  It is not required that participants be discontinued from their anti -platele t agent 
in order to screen and enroll in the study.  
 
A minimal total volume of CSF ( 25 ml) will be required  for this study.  To clear any blood from minor 
trauma associated with needle insertion, the first 1 -2 mL of CSF are discarded (or more if 
needed) .  Collected CSF is aliquoted into sterile microtube s. Approximately 2ml of CSF or volume per 
local laboratory requirements will be sent at ambient  temperature  to the CRU  laboratory for protein, 
glucose and cell count. The remaining CSF will be immediately frozen upright on dry ice for at least 20 
minutes then stored at -70 until analysis.  
 
CSF samples will be used to measure levels of insulin, A42, A40, total tau , and phospho -tau181 . 
Assays will be performed by [CONTACT_419287] . CSF samples will also be 
frozen and stored for future analysis of putative biomarkers . 
07-December -2020  
IND #:  [ADDRESS_528711].  
Blood samples will be collected before CSF collection, which would be processed for fasting plasma 
insulin, glucose, A 42, and A 40. Additional blood for plasma  and serum will be proces sed and bank ed. 
 
10.[ADDRESS_528712]. Don Bowden under 
the auspi[INVESTIGATOR_419260] .  
 
11.0 STATISTICAL PLAN  
Statistical analyses will be conducted by [CONTACT_419288]. To address the Primary Aim , 
CSF insulin values will be subjected to a repeated measures analysis of variance with treatment (saline 
vs. placebo) as the repeated measure, with age and baseline MMSE as covariates. Secondary analyses 
will examine the effect of diagnostic status (cogniti vely normal vs. MCI) and APOE genotype. Secondary 
analyses will also examine treatment -related differences for other CSF and plasma biomarkers, and for 
memory scores.  
 
11.[ADDRESS_528713] not been conducted. However,  the 
proposed sample size is larger than two previous studies (Born et al. 2002; Fishel et al. that showed 
that administering insulin increased CSF insulin levels.  
 
12.[ADDRESS_528714] been extensively 
explored for over two decades  (Pontiroli, Alberetto et al. 1982 ). For diabetes treatment, absorption  
enhancers must be used to increase the transport of insulin across the nasal membrane to the periphery 
due to the fact that peripheral bioavailablity of insulin without absorption enhancers is less than 1%  
(Illum 2002 ). A recent safety study of INI administration without absorption enhancers demonstrated no 
treatment  induced changes in blood glucose levels, nasal airway patency, or transnasal pressure 
gradient  (Kupi[INVESTIGATOR_23057], Sipi[INVESTIGATOR_360913]. 2003 ). There are no known serious risks associated with INI without 
enhancers. A recent industry report raised the issue of rare but significant increases in lung cancer in 
smokers treated with inhaled insulin; six of 4740 patients taking inhaled insulin develope d lung cancer 
compared with one of 4292 patients who received an active comparator  (incidence per 100 patient 
years exposure, 0.13 vs 0.02). However, the inhaled insulin protocol used for diabetes treatment in this 
report included absorption enhancers to maximize delivery to lungs, whereas the nose -to-brain delivery 
device to be used in this study greatly minimizes lung delivery.  
 
Regarding the risk of hypoglycemia, at least five peer reviewed human studies  (Kern, Born et al. [ADDRESS_528715], de Fries 
et al. Submitted for publication )  and four preliminary studies (Reger, Watson et al. 2006 , Reger, Watson 
et al. 2008 , Reger, Watson et al. 2008 ) (Craft, Baker et al. 2012 ) revealed no change in blood glucose 
levels following intranasal insulin administration with doses that included 40 International Units  4 times 
daily for two months . There was  one exception with the case of a single participant who experienced 
mild hypoglycemia (52 mg/dl) after skippi[INVESTIGATOR_007] a meal and engaging in sustained  vigorous exercise. In 
07-December -2020  
IND #:  119232  
Page 23 of 33 addition, a recent safety study (Kupi[INVESTIGATOR_23057], Sipi[INVESTIGATOR_360913]. 2003 ) examined intranasal insulin administration of 
[ADDRESS_528716] 
patency and transna sal pressure gradient. Results indicated no change in blood glucose values with 
insulin, and no change in the frequency of glucose values above 3.0 mmol/L. The only symptomatic 
hypoglycemic value occurred during placebo treatment. Insulin treatment had  no effect on other 
laboratory values (C -peptide, total cholesterol, HDL, LDL, triglycerides, creatinine, glutamyl 
transferase), blood pressure, or body weight. In addition, nasal examinations revealed no adverse 
effects or functional disturbances following  intranasal insulin administration. No serious adverse effects 
of treatment were observed in the preliminary studies  (Reger, Watson et al. 2006 , Reger, Watson et al. 
2008 , Reger, Watson et al. 2008 , Craft, Baker et al. 2012 ). 
 
12.2 Risks associated with use of the ViaNase® device  
Because the use of the device will be supervised directly by [CONTACT_419289] . Participants  could experience some discomfort to their eyes or face if they do not hold 
the device to their nose as directed ; however, again, the study nurse will carefully instruct and oversee 
device use so that any errors can be immediately corrected .  
 
12.3 Lumbar Puncture  
Lumbar puncture may be associated with pain during the performance of the procedure. This is usually 
temporary and confined to the lower back. Headache may occur in about 5% of elderly people who 
undergo lumbar puncture. Less commonly, in about 1 -4% of par ticipants, a persistent low -pressure 
headache may develop, probably due to leakage of CSF. Lower rates of post -LP headache have been 
noted in elderly patients, and when atraumatic (Sprotte) needles are used. If a post -LP headache 
persists it may need addit ional treatment, e.g. with fluids and analgesics. Uncommonly a blood patch 
(injection of some of the participant’s blood to patch the CSF leak) may be needed. Potential but rare 
risks of lumbar puncture include infection, damage to nerves in the back, and bleeding into the CSF 
space. The risk of these is much less than 1%.   
 
12.[ADDRESS_528717] the protocol.   
 
▪ Principal Investigator : [INVESTIGATOR_89885] (PI ; Suzanne Craft, PhD ) is responsible for the 
overall conduct of the study. The PI [INVESTIGATOR_419261]. The PI [INVESTIGATOR_419262] a high level of skill and accuracy in conducting assessments.  
▪ Study Physician : Benjamin Williams, MD, PhD will serve as Study Physician for the trial. He will 
be responsible for conducting and supervising the medical evaluation ( nasal examination, physical 
and neurological examinations), reviewing adverse events, interpreting laboratory results, and 
supervising clinical care provided to the participant during the study . He will also supervise, and on 
some occasions may perform the lumbar punctures . 
▪ Study Nurse/ Coordinator:  Deborah Dahl, RN will serve as Study Nurse/Coordinator for the trial. 
She will be responsible for managing the day -to-day conduct of the trial.  Duties may include tracking 
recruitment, ensuring accurate administration of all instruments at the site, maintaining case report 
07-December -2020  
IND #:  119232  
Page 24 of 33 forms, processing of laboratory samples, and coordinating clinic visits . She will also oversee the use 
and maintenance of the devices, and coordinate with the Pharmacy regarding ordering and storage 
of saline and insulin.  
▪ Interviewer/Psychometrician:  This person will be responsible for administering the memory  
assessments.   
▪ CDR Rater:  This person wil l render the CDR -SB rating bas ed on clinical assessment of parti cipant 
and study participant .  
▪ Regulatory  Affairs:  Sarah Bohlman  will be responsible for managing all regulatory related 
documents for the duration of the trial. 
 
14.0 STUDY DRUG  
All participants will take receive one  dose of INI (20 International Units ) or placebo , administered 
approximately 30  minutes prior to the LP .  
 
14.1 Humulin® R U-100 Insulin  
Humulin® R U-100 (NDC: 0002 -8215, Eli Lilly & Company)  is a polypeptide hormone structurally 
identical to human insulin synthesized through rDNA technology in a special non -disease -producing 
laboratory strain of Escherichia coli bacteria. Humulin R U -100 has the empi[INVESTIGATOR_62497] 
C257H383N65O77S6 and a molecular weight of 5808  Da. Humulin R U -100 is a sterile, clear, aqueous, and 
colorless solution that contains human insulin (rDNA origin) 100 units/mL, glycerin 16 mg/mL and 
metacresol 2.5 mg/mL, endogenous zinc (approximately 0.015 mg/100 units) and water for injection. 
The pH is 7.0 to 7.8. Sodium hydroxide and/or hydrochloric acid may be added during manufacture to 
adjust the pH.  
 
More information about the Humulin® R U-100 insulin, including risks, contraindication and adverse 
reactions can be found in the the US package insert (USPI).  
 
14.2 Placebo (Sterile Saline ) 
The placebo  will consist of sterile saline . 
 
14.3 Randomization  
Eligible participants will be randomized on a 1:[ADDRESS_528718].  
 
14.4 Blinding  
Neither participants  or site personnel will know whether insulin or saline is being administered. 
Exception s will be  the study nurse who is directly involved in preparing the insulin or placebo, as well 
as preparing DSMB reports . 
  
14.5 Study Drug Dispensing  
Study drug will be inserted  into the chamber of the Via NaseTM by [CONTACT_74309] . 
 
14.6 Intranasal Administration  
Insulin  or placebo  will be administered with a ViaNaseTM drug delivery device ( Kurve Technology, 
Bothell, WA ). ViaNaseTM specifically target s olfactory delivery to maximize drug transport to the CNS. 
This device releases a metered insulin dose into a chamber covering the participant ’s nose . The insulin  
or placebo  is then inhaled by [CONTACT_419290] a specified  period. This method allows 
administration of smaller particle sizes to increase deposition in the upper nasal cavity while minimizing 
transport to the lungs. A volume of about  0.7 mL of insulin or placebo will be administered each time.  
 
14.7 Storage   
Insulin and placebo will be maintained  at a controlled temperature . 
 
07-December -2020  
IND #:  119232  
Page 25 of 33 14.8 Drug Accountability   
The study nurse coordinator will maintain a log of study drug usage.   
 
15.0 ADVERSE EVENTS  
 
15.1 Definition  
An adverse event (AE) is defined as per the Code of Feder al Regulation Title 21 Part 312.  
 
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=312.32  
 
Adverse events which occur after informed consent is signed include but are not limited to: (1) 
worsening or change in nature, severity, or frequency of conditions or symptoms present at the start of 
the study; (2) participant deterioration due to primary illness; (3) intercurrent illness; and (4) drug 
interaction. An abnormal laboratory value will only be reported as an AE if the  investigator considers it 
to be an AE, or if it leads to the participant being withdrawn from the study.  
 
The investigator should attempt to establish a diagnosis of the event based on signs, symptoms, and  
or other clinical information. In such cases, the diagnosis should be documented as the AE and not the 
individual signs  or symptoms.  Symptoms and conditions present at the beginning of the study will be 
characterized, so that AEs can be defined as any new symptom, or any increase in frequency or severity 
of an existing symptom.  
 
Following questioning and evaluation, all AEs, whether determined to be related or unrelated to the 
study drug by a medically qualified site PI [INVESTIGATOR_360920]  (MD, DO, NP or PA), must be documented in the 
participant’s medical records, in accordance with the investigator’s normal clinical practice, and on the 
AE e-CRF. Each AE is evaluated for duration, severity, seriousness, and causal relationship to the study 
drug.  
 
15.[ADDRESS_528719]  DSMB . Adverse events  will be 
rated as mild, moderate or severe.  This will also pertain to abnormal laboratory values  deemed clini cally 
significant by [CONTACT_7554] .  
 
16.0 SERIOUS ADVERSE EVENTS (SAE)  
 
16.1 Definition  
A serious adverse event is defined as per the Code of Federal Regulation Title 21 Part 312  
 
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=312.32  
 
16.2 Reporting SAEs  
Any serious and adverse event due to any cause, which occurs during the course of the investigation 
(i.e. anytime after informed consent, regardless of study drug exposure), will be reported to the PI [INVESTIGATOR_419263] [ADDRESS_528720]  IRB and DSMB within 7 days of study personnel learning of the event . 
 
 
 
 
 
 
07-December -2020  
IND #:  119232  
Page 26 of 33 17.0 ETHICS & REGULATORY CONSIDERATIONS  
 
17.[ADDRESS_528721]  
Study investigators are charged with conducting this study in full conformity with: 
1. Good Clinical Practice (GCP) guidelines, as defined by [CONTACT_360965] (ICH) Guideline, Topic E6  
2. The [LOCATION_002] Code of Federal Regulations, Title 21, Part 50 (21CFR50) – Protection of 
Human Subjects  
3. 21CFR56  – Institutional Review Boards (IRBs)  
4. HIPAA  
5. State and Federal regulations and all other applicable local regulatory requirements and laws.    
 
Study personnel involved in conducting this study will be qualified by [CONTACT_8640], training and experience 
to perform their respective task(s)  in accordance with GCP.   
 
17.[ADDRESS_528722] (IRB)  
This protocol and the associated informed consent documents and recruitment material will be 
approved by [CONTACT_419291] 
(OHRP). Any amendments to the protocol or consent materials must also be approved before they are 
placed into use. The investigator shall notify the IRB of deviations from the protocol or serious a dverse 
events occurring at the site, in accordance with local procedures.  
 
17.3 Informed Consent & HIPAA  Authorization  
In obtaining and documenting informed consent, the investigator should comply with the applicable 
regulatory requirement(s), and should adhere to GCP and to the ethical principles that have their origin 
in the Declaration of Helsinki.  Prior to the beginni ng of the trial, the investigator should have the IRB’s 
written approval of the written informed consent form (ICF) and any other written information to be 
provided to participants.  Participants, their relatives, guardians, or authorized representatives a nd study 
partners will be given ample opportunity to inquire about the details of the study. Prior to a subject’s 
participation in the trial, the written informed consent form  and HIPAA Authorization  should be signed 
and personally dated by [CONTACT_127205]/or the subject’ s legally authorized representative, the study 
partner  and by [CONTACT_28490].  Participants should be 
provided a copy of the signed ICF.  
 
The informed consent will not only cover consent for the trial itself, but for the genet ic research, 
biomarker studies and biological sample storage. The consent for storage will includ e consent to access 
stored data  and biological samples for secondary analyses. Consent forms will specify that DNA and 
biomarker samples are for research purposes only; the tests on the DNA and biomarker samples are 
not diagnostic in nature and participants will never receive results.  
 
17.4 Participant  Confidentiality | HIPAA  
Participant confidentiality is strictly held in trust by [CONTACT_3486], research staff, and the 
sponsoring institution and their agents.  This confidentiality is extended to cover testing of biological 
samples and genetic tests in additio n to the clinical information relating to participants. The study 
protocol, documentation, data and all other information generated will be held in strict confidence.  No 
information concerning the study or the data will be released to any unauthorized thi rd party, without 
prior written approval. Any data, specimens, forms, reports, and other records that leave the site will be 
identified only by a subject identification number to maintain confidentiality.  All records will be kept in a 
locked file cabinet.  All computer entry and networking programs will be done using subject IDs  only. 
Information will not be released without written permission of the subject , except as necessary for 
monitoring by [CONTACT_1201], DSMB, FDA, NIA, and the OHRP.  
07-December -2020  
IND #:  [ADDRESS_528723] of 1996 (HIPAA).  Those regulations require a 
signed HIPAA A uthorization informing the subject  of the following:  
 
• What protected health information (PHI) will be collected from participants in this study  
• Who will have access to that information and why  
• Who will use or disclose that information  
• The rights of a research participant to revoke their authorization for use of their PHI.  
 
In the event that a subject  revokes authorization to collect or use PHI, the investigator, by [CONTACT_5151], 
retains the ability to use all information collected prior to the revocation of subject  authorization. Each 
site PI, under the guidance of his/her IRB, is responsible for ensuring that all applicable HIPAA 
regulations and State laws are met.  
 
18.0 GENETIC RESEARCH & STORAGE OF GENETIC MATERIAL  
The DNA is banked in locked freezers in the ADRC  Biomarker  Service .  Sample tubes are bar -coded 
and linked to participant ID number only and banked without personal identifiers .  
 
Only DNA from consenting participants will be banked and used to facilitate future research on aging 
and dementia, particularly in the discovery of genetic polymorphisms that may influence risk of 
developi[INVESTIGATOR_201314].  Collecti on of  DNA will permit investigators to probe candidate genetic polymorphisms 
as predictors of outcome in future studies.  The samples will be stored by [CONTACT_419292] .   
  
18.1 Storage of Biospecimen Samples  
All biospecimens being  banked for future AD biomarker research will be stored by [CONTACT_419293] .  
 
19.0 RISKS AND  BENEFITS ASSOCIATED WITH THIS STUDY  
 
19.1 Potential Benefits of the Proposed Research to Human Subjects  
There is an urgent need to identify promising treatments for patients with AD and its prodrome aMCI. 
In a previous trial  (Craft, Baker et al. 2012 ), intranasal insulin safely improved delayed memory and 
function in these patients. In a recent trial, these results were replicated with the subgroup of participants 
who used the ViaNase device, but not with the POD cohort. The proposed trial is designed to answer 
the important question of whether  the ViaNase device is effective in delivering  intranasal insulin into the 
CNS. This knowledge will enable the conduct of future Phase III trials of intranasal insulin.  
 
There are no significant potential clinical benefits for the participant s in this study. Rather, there is a 
clear scientific benefit for the field as a whole. T he relatively minor risks posed by [CONTACT_419294], cognitive testing, and LP are outweighed by [CONTACT_419295] . 
 
19.2 Inclusion of Women and Minorities  
There are currently no studies that definitively support or negate the existence of significant differences 
in response to intranasal insulin in subgroups defined by [CONTACT_419296]. A specific goal 
percentage for  women and minority enrollment is not set for this study . However, w e will  monitor minority 
enrollment  throughout the study  and make special effort to encourage minority enrollment . Minority 
enrollment will be  facilitated through minority outreach effort coordinated by [CONTACT_419297] . No participant  will be excluded due to his or her  sex, race, or ethnic group.  
 
19.3 Inclusion of Children as Participants in Research Involving Human Subjects  
Children will not be included.  
 
 
07-December -2020  
IND #:  [ADDRESS_528724] ( I-DSMB), which will be responsible for monitoring the safety of research 
participants.  
 
The WFUHS Institutional Data & Safety Monitoring Board (I -DSMB) is a Dean -appointed multi -
disciplinary, standing committee that is available to provide independent oversight for human research 
studies conducted by [CONTACT_419298] -affiliated faculty investigators. I ‐DSMB 
recommendations are reported to the study PI, who is responsible for forwarding them to the IRB and 
to the study sponsor.   
 
While most I -DSMB reviews are conducted via electronic interactions, face -to-face meetings would 
occur as needed (e.g., for unplanned interim analyses, based on safety concerns).  
All individual study discussions (online or face -to-face) are preceded by [CONTACT_419299] I ‐DSMB 
members have either a perceived or actual conflict of interest that could bias their ability to objectively 
monitor and make judgments about the study. Actual conflicts would mandate recusal from all closed ‐
session discussions and relinquishment of voting for the study, while perceived conflicts may be dealt 
with by [CONTACT_419300]. Conflict of interest (COI) 
management of studies monitored by [CONTACT_941] I ‐DSMB will be determined on a case ‐by‐case basis.  
 
Information regarding serious adverse events (SAEs) will be present ed to the DSMB every six 
months . The DSMB may recommend stoppi[INVESTIGATOR_419264] a treatment  difference in adverse events.  Recommendations of the DSMB 
after each review will be presented to the study PI [INVESTIGATOR_32397]. Participants will be screened at the 
beginning of the study and will be monitored carefully at each study visit.   
 
20.[ADDRESS_528725] of the Protocol Committee,  interested 
Principal Investigators and appropriate ADCS personnel .  The committee will solicit input and 
assistance from other Investigators as appropriate and adhere to all ADCS Publications Policies.  
 
21.0 SHARING OF FINAL RESEARCH DATA  
Data from this research will be shared with other researchers pursuant to the 02/26/2003 “NIH Final 
Statement on Sharing Research Data”. NIH believes that data sharing is important for further translation 
of research results into knowledge, products, and p rocedures to improve human health.  The NIH 
endorses the sharing of final research data to serve these and other important scientific goals.  To 
protect subjects ’ rights and confidentiality, identifiers will be removed from the data before they are 
shared.  
 
 
 
 
 
 
 
 
 
 
 
 
 
07-December -2020  
IND #:  119232  
Page 29 of 33 22.0 TABLE 4: SCHEDULE OF PROCEDURES AND ASSESSMENTS  
 
Visit #  [ADDRESS_528726]  X   
Adverse Events  X X X 
Blood Draw  X   
- Clinical Labs  X   
- ApoE Genotypi[INVESTIGATOR_007] | DNA Banking1 X   
- Biomarkers | Plasma|Serum | Sample Banking   X X 
LP  X X 
- CSF Biomarkers | Banking2  X X 
- post-procedure safety telephone check   X X 
Auditory Verbal Learning Test   X X 
1DNA banking is optional  
2CSF banking is optional  
07-December -2020  
IND #:  [ADDRESS_528727], R. C. Petersen, P. J. Snyder, M. C. Carrillo, B. Thies and C. H. Phelps 
(2011). "The diagnosis of mild cognitive impairment due to Alzhei mer's disease: Recommendations 
from the National Institute on Aging and Alzheimer's Association workgroup." Alzheimers Dement . 
Baker, H. and R. F. Spencer (1986). "Transneuronal transport of peroxidase -conjugated wheat germ 
agglutinin (WGA -HRP) from the olfactory epi[INVESTIGATOR_360922]." Exp Brain Res  63(3): 
461-473. 
Baker, L. D., D. J. Cross, S. Minoshima, D. Belongia, G. S. Watson and S. Craft (2011). "Insulin 
resistance and Alzheimer -like reductions in regional cerebral glucose metabolism for cognitively 
normal adults with prediabetes or early type 2 diabetes." Arch Neurol  68(1): 51 -57. 
Balin, B. J., R. D. Broadwell, M. Salcman and M. el -Kalliny (1986). "Avenues for entry of peripherally 
administered protein to the central nervous system in mouse, rat, and squirrel monkey." J Comp 
Neurol  251(2): [ADDRESS_528728], C., M. Hallschmid, A. Hatke, B. Schultes, H. L. Fehm, J. Born and W. Kern (2004). 
"Intranasal insulin improves memory in humans." Psychoneuroendocrinology  29(10): [ADDRESS_528729], C., W. Kern, B. Schultes, J. Born and M. Hallschmid (2008). "Differential sensitivity of men 
and women to anorexigenic and memory -improving effects of intranasal insulin." J Clin Endocrinol 
Metab  93(4): 1339 -1344.  
Bodian, D. and H. A. Howe (1941). "Experimental studies on intraneuronal spread of poliomyelitis 
virus." Bull Johns Hopkins Hosp  68: 248 -267. 
Born, J., T. Lange, W. Kern, G. P. McGregor, U. Bickel and H. L. Fehm (2002). "Sniffing 
neuropeptides: a transnasal approach to the human brain." Nat Neurosci  5(6): 514 -516. 
Broadwell, R. D. and B. J. Balin (1985). "Endocytic and exocytic pathways of the neuronal secretory 
process and trans -synaptic transfer of wheat germ agglutinin -horseradish peroxidase in vivo." J Comp 
Neurol  242(4): 632 -650. 
Cavanna, A. E. and M. R. Trimble (2006). "The precuneus: a review of its functional anatomy and 
behavioural correlates." Brain  129(Pt 3): 564 -583. 
Chiu, S. L., C. M. Chen and H. T. Cline (2008). "Insulin receptor signaling regulates synapse number, 
dendritic plasticity, and circuit function in vivo." Neuron  58(5): 708 -719. 
Craft, S., L. D. Baker, T. J. Montine, S. Minoshima, G. S. Watson, A. Claxton, M. Arbuckle, M. 
Callaghan, E. Tsai, S. R. Plymate, P. S. Green, J. Leverenz, D. Cross and B. Gerton (2012). 
"Intranasal insulin therapy for Alzheimer disease and amnestic mild c ognitive impairment: a pi[INVESTIGATOR_419265]." Arch Neurol  69(1): 29 -38. 
Craft, S., L. D. Baker, T. J. Montine, S. Minoshima, G. S. Watson, A. Claxton, M. Arbuckle, M. 
Callaghan, E. Tsai, S. R. Plymate, P. S. Green, J. Leverenz, D. J. Cross and B. Gerton (2012). 
"Intranasal Insulin Therapy for AD and MCI: A Pi[INVESTIGATOR_174107] ." Arch Neurol  69: 29-38. 
Craft, S., E. Peskind, M. W. Schwartz, G. D. Schellenberg, M. Raskind and D. Porte, Jr. (1998). 
"Cerebrospi[INVESTIGATOR_419266]'s disease: relationship to severity of 
dementia and apolipoprotein E genotype." Neurology  50(1): 164 -168. 
Craft, S. and G. S. Watson (2004). "Insulin and neurodegenerative disease: shared and specific 
mechanisms." Lancet Neurol  3(3): 169 -178. 
De Felice, F. G., M. N. Vieira, T. R. Bomfim, H. Decker, P. T. Velasco, M. P. Lambert, K. L. Viola, W. 
Q. Zhao, S. T. Ferreira and W. L. Klein (2009). "Protection of synapses against Alzheimer's -linked 
toxins: insulin signaling prevents the pathogenic bind ing of Abeta oligomers." Proc Natl Acad Sci U S 
A 106(6): 1971 -1976.  
Faber, H. K. (1938). "The early lesions of poliomyelitis after intranasal inoculation." J Pediat  13(1): [ADDRESS_528730] (1930). "The pathogenesis of, and propagation of the virus in, 
experimental poliomyelitis." J Path Bact  33: 17-45. 
07-December -2020  
IND #:  [ADDRESS_528731];62(10): 1539 -44. "Hyperinsulinemia provokes synchronous increases in central 
inflammation and beta -amyloid in normal adults. " 
Francis, G. J., J. A. Martinez, W. Q. Liu, K. Xu, A. Ayer, J. Fine, U. I. Tuor, G. Glazner, L. R. Hanson, 
W. H. Frey, 2nd and C. Toth (2008). "Intranasal insulin prevents cognitive decline, cerebral atrophy 
and white matter changes in murine type I diabeti c encephalopathy." Brain  131(Pt 12): 3311 -3334.  
Frey, W. H. (2002). "Intranasal delivery: By[CONTACT_360982] -brain barrier to deliver therapeutic 
agents to the brain and spi[INVESTIGATOR_1831]." Drug Delivery Technology  2(5): 46 -49. 
Frolich, L., D. Blum -Degen, H. G. Bernstein, S. Engelsberger, J. Humrich, S. Laufer, D. Muschner, A. 
Thalheimer, A. Turk, S. Hoyer, R. Zochling, K. W. Boissl, K. Jellinger and P. Riederer (1998). "Brain 
insulin and insulin receptors in aging and sporadic A lzheimer's disease." J Neural Transm  105(4-5): 
423-438. 
Galasko, D., D. Bennett, M. Sano, C. Ernesto, R. Thomas, M. Grundman and S. Ferris (1997). "An 
inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's 
Disease Cooperative Study." Alzheimer Dis Assoc Disord  [ADDRESS_528732] 2 : S33 -39. 
Gasparini, L., G. K. Gouras, R. Wang, R. S. Gross, M. F. Beal, P. Greengard and H. Xu (2001). 
"Stimulation of beta -amyloid precursor protein trafficking by [CONTACT_360983] -
amyloid and requires mitogen -activated protein kinase signaling."  J Neurosci  21(8): 2561 -2570.  
Gil-Bea, F. J., M. Solas, A. Solomon, C. Mugueta, B. Winblad, M. Kivipelto, M. J. Ramirez and A. 
Cedazo -Minguez (2010). "Insulin levels are decreased in the cerebrospi[INVESTIGATOR_419267]'s disease." J Alzheimers Dis  22(2): 405 -413. 
Grillo, C. A., G. G. Pi[INVESTIGATOR_342813], R. M. Hendry and L. P. Reagan (2009). "Insulin -stimulated translocation of 
GLUT4 to the plasma membrane in rat hippocampus is PI3 -kinase dependent." Brain Res  1296 : 35-
45. 
Hallschmid, M., C. Benedict, B. Schultes, J. Born and W. Kern (2008). "Obese men respond to 
cognitive but not to catabolic brain insulin signaling." Int J Obes (Lond)  32(2): 275 -282. 
Hong, M. and V. M. Lee (1997). "Insulin and insulin -like growth factor -1 regulate tau phosphorylation 
in cultured human neurons." J Biol Chem  272(31): [ZIP_CODE] -[ZIP_CODE].  
Hughes, C. P., L. Berg, W. L. Danziger, L. A. Coben and R. L. Martin (1982). "A new clinical scale for 
the staging of dementia." Br J Psychiatry  140: 566 -572. 
Illum, L. (2002). "Nasal drug delivery: new developments and strategies." Drug Discov Today  7(23): 
1184 -1189.  
Kern, W., J. Born, H. Schreiber and H. L. Fehm (1999). "Central nervous system effects of intranasally 
administered insulin during euglycemia in men." Diabetes  48(3): 557 -563. 
Kristensson, K. and Y. Olsson (1971). "Uptake of exogenous proteins in mouse olfactory cells." Acta 
Neuropathol  19(2): 145 -154. 
Kupi[INVESTIGATOR_23057], A., J. Sipi[INVESTIGATOR_23057], P. Keskinen, T. Simell, M. Knip, K. Pulkki and O. Simell (2003). "Intranasally 
administered insulin intended for prevention of type 1 diabetes --a safety study in healthy adults." 
Diabetes Metab Res Rev  19(5): 415 -420. 
Lee, C. C., Y. M. Kuo, C. C. Huang and K. S. Hsu (2009). "Insulin rescues amyloid beta -induced 
impairment of hippocampal long -term potentiation." Neurobiol Aging  30(3): 377 -387. 
Minoshima, S., K. A. Frey, N. L. Foster and D. E. Kuhl (1995). "Preserved pontine glucose metabolism 
in Alzheimer disease: a reference region for functional brain image (PET) analysis." J Comput Assist 
Tomogr  19(4): 541 -547. 
Minoshima, S., R. A. Koeppe, K. A. Frey and D. E. Kuhl (1994). "Anatomic standardization: linear 
scaling and nonlinear warpi[INVESTIGATOR_360927]." J Nucl Med  35(9): 1528 -1537.  
Morris, J. C. (1993). "The Clinical Dementia Rating (CDR): current version and scoring rules." 
Neurology  43(11): 2412 -2414.  
Morris, J. C., C. Ernesto, K. Schafer, M. Coats, S. Leon, M. Sano, L. J. Thal and P. Woodbury (1997). 
"Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's Disease 
Cooperative Study experience." Neurology  48(6): 1508 -1510.  
07-December -2020  
IND #:  119232  
Page 32 of 33 Petersen, R. C., R. Doody, A. Kurz, R. C. Mohs, J. C. Morris, P. V. Rabins, K. Ritchie, M. Rossor, L. 
Thal and B. Winblad (2001). "Current concepts in mild cognitive impairment." Arch Neurol  58(12): 
1985 -1992.  
Pontiroli, A. E., M. Alberetto, A. Secchi, G. Dossi, I. Bosi and G. Pozza (1982). "Insulin given 
intranasally induces hypoglycaemia in normal and diabetic subjects." Br Med J (Clin Res Ed)  
284(6312): 303 -306. 
Reger, M. A., G. S. Watson, W. H. Frey, 2nd, L. D. Baker, B. Cholerton, M. L. Keeling, D. A. Belongia, 
M. A. Fishel, S. R. Plymate, G. D. Schellenberg, M. M. Cherrier and S. Craft (2006). "Effects of 
intranasal insulin on cognition in memory -impaired older  adults: modulation by [CONTACT_15335]." 
Neurobiol Aging  27(3): 451 -458. 
Reger, M. A., G. S. Watson, P. S. Green, L. D. Baker, B. Cholerton, M. A. Fishel, S. R. Plymate, M. M. 
Cherrier, G. D. Schellenberg, W. H. Frey and S. Craft (2008). "Intranasal insulin administration dose -
dependently modulates verbal memory and plasma amyl oid-beta in memory -impaired older adults." 
Journal of Alzheimers Disease  13(3): 323 -331. 
Reger, M. A., G. S. Watson, P. S. Green, C. W. Wilkinson, L. D. Baker, B. Cholerton, M. A. Fishel, S. 
R. Plymate, J. C. Breitner, W. DeGroodt, P. Mehta and S. Craft (2008). "Intranasal insulin improves 
cognition and modulates beta -amyloid in early AD." Neurology  70(6): 440 -448. 
Rivera, E. J., A. Goldin, N. Fulmer, R. Tavares, J. R. Wands and S. M. de la Monte (2005). "Insulin 
and insulin -like growth factor expression and function deteriorate with progression of Alzheimer's 
disease: link to brain reductions in acetylcholine." J Alzheimers Dis  8(3): 247 -268. 
Rubin, D. B. (1987). Multiple Imputation for Nonresponse in Surveys . Hoboken, New Jersey, John 
Wiley & Sons, Inc.  
Sakane, T., M. Akizuki, Y. Taki, S. Yamashita, H. Sezaki and T. Nadai (1995). "Direct drug transport 
from the rat nasal cavity to the cerebrospi[INVESTIGATOR_872]: the relation to the molecular weight of drugs." J 
Pharm Pharmacol  47(5): 379 -381. 
Sano, M., R. Raman, J. Emond, R. G. Thomas, R. Petersen, L. S. Schneider and P. S. Aisen (2011). 
"Adding Delayed Recall to the Alzheimer Disease Assessment Scale is Useful in Studies of Mild 
Cognitive Impairment But Not Alzheimer Disease." Alzheimer Dis Assoc Disord  25(2): 122 -127. 
Selkoe, D. J. (2008). "Soluble oligomers of the amyloid beta -protein impair synaptic plasticity and 
behavior." Behav Brain Res  192(1): 106 -113. 
Shipley, M. T. (1985). "Transport of molecules from nose to brain: transneuronal anterograde and 
retrograde labeling in the rat olfactory system by [CONTACT_360985] -horseradish peroxidase 
applied to the nasal epi[INVESTIGATOR_2130]." Brain Res Bull  15(2): [ADDRESS_528733], U., D. de Fries, Y. Schottenfeld -Naor, A. Huebinger, H. J. Steingrueber and W. A. 
Scherbaum (Submitted for publication). "Intranasally administered insulin and its CNS effects in 
healthy humans: unconditioned and conditioned responses."  
Stockhorst, U., D. de Fries, H. J. Steingrueber and W. A. Scherbaum (2004). "Insulin and the CNS: 
effects on food intake, memory, and endocrine parameters and the role of intranasal insulin 
administration in humans." Physiol Behav  83(1): 47 -54. 
Talairach, J. and P. Tournoux (1988). Co-planar stereotaxic atlas of the human brain: 3 -dimensional 
proportional system: an aproach to cerebral imaging . [LOCATION_001], [LOCATION_001], Thieme Medical 
Publishers.  
Thorne, R. G., C. R. Emory, T. A. Ala and W. H. Frey, 2nd (1995). "Quantitative analysis of the 
olfactory pathway for drug delivery to the brain." Brain Res  692(1-2): 278 -282. 
Thorne, R. G., G. J. Pronk, V. Padmanabhan and W. H. Frey, 2nd (2004). "Delivery of insulin -like 
growth factor -I to the rat brain and spi[INVESTIGATOR_419268]." Neuroscience  127(2): 481 -496. 
Townsend, M., T. Mehta and D. J. Selkoe (2007). "Soluble Abeta inhibits specific signal transduction 
cascades common to the insulin receptor pathway." J Biol Chem  282(46): [ZIP_CODE] -[ZIP_CODE].  
Weiss, P. and Y. Holland (1967). "Neuronal dynamics and axonal flow, ii. The olfactory nerve as 
model test object." Proc Natl Acad Sci U S A  57(2): 258 -264. 
07-December -2020  
IND #:  119232  
Page 33 of 33 Worsley, K. J., A. C. Evans, S. Marrett and P. Neelin (1992). "A three -dimensional statistical analysis 
for CBF activation studies in human brain." J Cereb Blood Flow Metab  12(6): 900 -918. 
Zhao, L., B. Teter, T. Morihara, G. P. Lim, S. S. Ambegaokar, O. J. Ubeda, S. A. Frautschy and G. M. 
Cole (2004). "Insulin -degrading enzyme as a downstream target of insulin receptor signaling cascade: 
implications for Alzheimer's disease intervention." J Neurosci  24(49): [ZIP_CODE] -[ZIP_CODE].  
Zhao, W. Q. and M. Townsend (2009). "Insulin resistance and amyloidogenesis as common molecular 
foundation for type 2 diabetes and Alzheimer's disease." Biochim Biophys Acta  1792 (5): 482 -496. 
 